Heat Biologics, Inc (NASDAQ: HTBX) is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
Location: United States, North Carolina, Durham
Employees: 11-50
Phone: +1 919-240-7133
Total raised: $9M
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | Seed-One C... | seedone.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 17.04.2013 | - | $5M | - |
| 03.01.2012 | - | $4M | - |
Mentions in press and media 18
| Date | Title | Description |
| 12.04.2021 | HEAT BIOLOGICS, INC. Heat Biologics : Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Can... | Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021 Download as PDFApril 12,... |
| 09.02.2021 | HEAT BIOLOGICS, INC. Heat Biologics : Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial | February 9, 2021 Heat Biologics Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial Median overall survival of 24.6 months in previously treated checkpoint inhibitor naïve non-small cell lun... |
| 09.02.2021 | Heat Biologics : Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial | February 9, 2021 Heat Biologics Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial Median overall survival of 24.6 months in previously treated checkpoint inhibitor naïve non-small cell lun... |
| 16.04.2020 | Covid-19 vaccine tracker updated to include GSK/Sanofi collaboration | By Jeff Craven Currently, there are no FDA-approved therapies or vaccines for SARS-CoV-2, the virus that causes Covid-19. The National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes... |
| 09.04.2020 | Covid-19 Tracker updates vaccine candidates | By Jeff Craven On March 11, the World Health Organization classified the Covid-19 outbreak as a pandemic. The disease has reached nearly every country, infecting hundreds of thousands of people and killing thousands. Curr... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
| 07.04.2016 | Heat Biologics to slash staff by a fifth, cut more than half of patients in cancer trial | Another day, another biotech announces "cost-saving measures"--this time, it's immuno-oncology specialist Heat Biologics ($HTBX) wielding the ax. The Durham, NC-based biotech said in a statement that it will be cutting around 22% ... |
| 17.04.2013 | Heat Biologics gets $5M to usher heat shock protein therapy into phase 2 lung cancer trials | Unlike other immunotherapies that use a patient’s own cells or blood, Heat’s technology, ImPACT, is designed to be an off-the-shelf product. Currently, Heat is recruiting patients for a phase 2 study in late-stage, non-small cell lung cance... |
| 16.02.2012 | Life sciences companies make pharma pitches, hope for hits with investors | Heat Bio. Heat’s lead drug program is an experimental lung cancer treatment in phase 2 clinical trials. Heat Bio’s proprietary technology reprograms tumor cells to pump out antigens to fight disease. CEO Jeff Wolf said that when the company... |
| 15.02.2012 | Pharmas, medical device makers set to pitch at CED Life Science conference | A total of 16 companies are scheduled to make presentations, split evenly between pharmaceuticals and medical devices. Here’s a quick rundown of the presenting companies, all of whom are either based in North Carolina’s Research Triangle or... |
Show more